iNtODEWORLD’s Chief Operating Officer, H. Tim Min, and Project Coordinator, Minerva Marcano, will be attending the 2nd inaugural Phage Futures Congress 2020 being held in Washington D.C. from February 5-6, 2020. The conference is first of its kind to discuss how to translate phage-based application...
iNtRON Biotechnology attended the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14, 2020. J.P. Morgan’s Healthcare Conference is Wall Street’s premier investor conference aimed exclusively towards companies defining the healthcare industry. J.P. Morgan Healthcare Conference continues their tradition of...
Investment in the treatment of rare and orphan diseases continues to significantly grow as the pharmaceutical and biotech industry diverges their attention to novel drug development. Despite the momentous shift in attention to smaller patient populations affected by rare disease, Contract Research Organizations (CROs) now face...
Dr. Stephan Lory, microbial and molecular genetics professor at Harvard University, aims to understand the molecular basis of pathogenesis of human infections caused by opportunistic gram-negative bacteria. Lory’s research explores host-parasite relationship using P. aeruginosa model allowing examination of a variety of bacterial factors that lead to colonization,...
The head of the Lifetech Research Center, Dr. Kang, has received the ‘President Citation Award’ for his contribution to the Korean industry development of industry. iNtRON Biotechnology will try its best to become a global company in the ‘Diagnosis / Prevention / Therapeutics’ area. Thank you.
iNtRON Biotechnology and Estech Pharma today announced that they have entered into the collaboration agreement on eHeme (engineered Heme) technology development. According to iNtRON Bio, two companies will make an investment together in the bio and chemical production of eHeme based on the iNtRON Bio’s relevant patents....